For the treatment of angina
DOV diltiazem was developed at DOV Pharmaceutical. It is our proprietary formulation of diltiazem, a product candidate for the treatment of angina and hypertension. Diltiazem belongs to a well-known class of drugs called calcium channel blockers. DOV diltiazem combines an immediate release component with an extended release component in order to provide improved blood levels throughout the day compared to currently marketed diltiazem products.
The Company believes that DOV diltiazem will reduce morning angina attacks to a significantly greater extent than commercially available products because of its combination of immediate and extended release components. Data from three Phase I trials indicate that our formulation produced clinically relevant blood levels within 30 minutes of administration and resulted in higher blood levels in the morning than Tiazac. We plan to begin a Phase III clinical trial by the end of 2002 comparing our formulation to placebo and a currently marketed diltiazem formulation.
